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Abstract
Background: Stereotactic body radiation therapy (SBRT) has been an emerging non-invasive treatment modality for
patients with hepatocellular carcinoma (HCC) when curative treatments cannot be applied. In this study, we report
our clinical experience with Cyberknife SBRT for unresectable HCC and evaluate the efficacy and clinical outcomes
of this highly sophisticated treatment technology.
Methods: Between 2008 and 2012, 115 patients with unresectable HCC treated with Cyberknife SBRT were
retrospectively analyzed. Doses ranged from 26 Gy to 40 Gy were given in 3 to 5 fractions for 3 to 5 consecutive
days. The cumulative probability of survival was calculated according to the Kaplan-Meier method and compared
using log-rank test. Univariate and multivariate analysis were performed using Cox proportional hazard models.
Results: The median follow-up was 15.5 months (range, 2-60 months). Based on Response Evaluation and Criteria
in Solid Tumors (RECIST). We found that 48.7 % of patients achieved a complete response and 40 % achieved a
partial response. Median survival was 15 months (4-25 months). Overall survival (OS) at 1- and 2-years was 63.
5 %(54-71.5 %) and 41.3 % (31.6-50.6 %), respectively, while 1- and 2- years Progression-free Survival (PFS) rates
were 42.8 %(33.0-52.2 %) and 38.8 % (29.0-48.4 %). Median progression was 6 months (3-16 months). In-field
recurrence free survival at 1 and 2 years was 85.3 % (76.2-91.1 %) and 81.6 % (72.2-88.6 %), respectively, while the
1- and 2-years out-field recurrence free survival were 52.5 % (41.2-60.8 %) and 49.5 %(38.9-59.2 %), respectively.
Multivariate analysis revealed that Child-Pugh score (A vs. B), Portal vein tumor thrombosis (positive vs. negative),
Tumor size (≤4 cm vs >4-9 cm /≥10 cm), and tumor response after SBRT (CR vs. PR/stable) were independent
predictors of OS. Acute toxicity was mostly transient and tolerable.
Conclusions: Cyberknife SBRT appears to be an effective non-invasive treatment for local unresectable HCC with
low risk of severe toxicity. These results suggested that Cyberknife SBRT can be a good alternative treatment for
unresectable HCC unsuitable for standard treatment.
Keywords: Cyberknife, Stereotactic body radiation therapy, Hepatocellular carcinoma
* Correspondence: jennyque28@yahoo.com.tw
1Department of Radiation Oncology, Chi Mei Medical Center, No.901,
Zhonghua RoadYongkang district, Tainan 710, Taiwan
Full list of author information is available at the end of the article
© 2016 Que et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Que et al. BMC Cancer  (2016) 16:451 
DOI 10.1186/s12885-016-2512-x
Background
Hepatocellular carcinoma (HCC) is the sixth most
common cancer and the third most common cause of
cancer-related death worldwide [1]. Surgical resection,
liver transplant, or radiofrequency ablation for the
treatment of tumors ≤ 3 cm are the only curative treat-
ment [2, 3]. Only a minority of patients are candidates for
these treatments due to multifocal intrahepatic recur-
rence, extrahepatic extension, major vascular invasion, or
impaired liver function caused by underlying cirrhosis. For
patients not suitable for curative treatment, TACE was the
most common alternative treatment. Although it does not
completely eradicate HCC, it is an effective palliative regi-
men with improved survival compared with the best
supportive care. However, for large (≥5 cm) or multiple
tumors, HCC with portal vein thrombosis, and extrahe-
patic metastasis, TACE is less effective [4, 5]. For these
patients, the use of sorafenib can increase 1-year survival
to 45 %. The SHARP (Sorafenib hepatocellular Carcinoma
Assessment Randomized Protocol) trial used sorafenib, a
multikinase inhibitor, as an effective systemic treatment
for advanced HCC, conferring an improvement in median
survival of 2.8 months compared with placebo. However,
invariable progression of the lesions was found among the
patients treated with TACE or sorafenib [6, 7].
Historically, radiation therapy (RT) was not recom-
mended for HCC patients because of the low tolerance
of the liver to radiation and the difficulty in localizing
tumors as a result of organ motion. However, with re-
cent technological advancements such as stereotactic
body radiation therapy (SBRT) and image-guided radio-
therapy, tumoricidal doses can be delivered safely to
the focal HCC while sparing the normal liver. Previ-
ously published data have yielded promising results,
achieving high local control and acceptable rates of
radiation-related toxicity [8, 9]. Although SBRT in the
management of HCC has been increasingly recognized,
there remain several questions to be answered. One of
these involves the identification of prognostic factors to
better understand and improve the outcome of SBRT
for HCC.
Cyberknife robotic radiotherapy (Accuray Inc, Sunnyvale,
CA, USA) with internal fiducial markers and synchrony
respiratory tracking capabilities allows more accurate
targeting by reducing the margin of error and normal
tissue exposure during therapy and therefore increases
the chances of treating larger tumors with limited normal
liver volume available or tumors are in close proximity
to critical organs. Cyberknife is a frameless whole-body
image guided robotic radiosurgery system that has a
6MV linear accelerator mounted on a computer con-
trolled robotic arm and an orthogonal pair of diagnostic X-
ray imaging devices. It can irradiate the target using 1200
points in the room [10–12], thereby, has the advantages to
delivering higher doses to the target while avoiding doses to
the normal structures.
In this study, we retrospectively analyzed the outcomes
and prognostic factors affecting survival in 115 unresect-




Between December 2008 and November 2012, 115 pa-
tients with unresectable HCC were treated with Cyber-
knife SBRT. Patients were included based on the following
criteria (1) Pathological confirmation of HCC, (2) At least
one radiological image showing the classic HCC enhance-
ment with alpha fetoprotein (AFP) >200 ng/ml or at least
2 radiological findings (CT/MRI/Angiogram) showing the
classic HCC, (3) the presentation of unresectable or med-
ically inoperable HCC, and (4) ECOG performance status
of ≤ 2. Patients with multiple extrahepatic metastases,
previous radiotherapy for liver tumors, SGOT and SGPT
levels of ≥ 2.5 times higher than the upper limit,
Child-Pugh score of ≥ 7, intractable ascites, tumor
closely attached to the esophagus, stomach, duodenum
and bowel, and a liver volume of less than 700 cc were
excluded from the study.
Mandatory elements included in the baseline examin-
ation are liver dynamic magnetic resonance imaging
(MRI) and/or Triphase computed tomography (CT),
complete blood study, liver function test, hepatitis B
and C virus testing, alpha-fetoprotein (AFP), and chest
images. Patients with HbsAg positive results or elevated
hepatitis B virus DNA were given prophylactic anti-
retroviral therapy from the start of SBRT to at least
6 months after the treatment for prevention of reactiva-
tion of HBV after radiotherapy [13–15].
The characteristics of the 115 patients and disease
variables at the time of radiation treatment are summa-
rized in Table 1. Median follow-up was 15 months (2-60
months). Their age ranges from 31-91 years, with a me-
dian age of 66 years and male predominance. Tumors
were mostly located in the right lobe. The maximum
tumor diameter ranged from 1.8- 18 cm.
Patients were explained the advantages and disadvan-
tages of cyberknife SBRT and made final treatment
decision for themselves. Written informed consent was
obtained from all patients before treatment, and the
study was approved by the institutional review board of
Chi Mei Medical Center.
SBRT
SBRT was performed using the Cyberknife, a robotic
image-guided whole-body radiosurgery system with the
synchrony respiratory tracking for targets that move
with respiration. Synchrony accuracy is less than 1.5 mm
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for mobile targets, with a treatment accuracy of 0.3 mm
[16]. 4 gold fiducial markers were implanted percutan-
eously around the perimeter of the target volume using
a sono-guided procedure 5-7 days before the planning
CT-scan. A Contrast simulation CT with slice thickness
of 1-mm was performed covering the whole liver and
bilateral kidneys. No Respiratory control and abdominal
compression was used. The image data were then trans-
ferred to the Cyberknife system’s treatment planning
workstation. Contouring was performed on the planning
CT images with contrast. To better delineate tumor vol-
umes, a set of MRI of liver was arranged in all patients,
hepatic or delayed phases of MRI were fused with the
planning CT scan for contouring, other phase images of
MRI were used as a visual reference. The system auto-
matically determined optimal beam directions and beam
weights in order to maximize the dose delivered to the
target and minimize that to the organs at risk. All pa-
tients were positioned on individually shaped vacuum
pillows and wore vests to which the optical markers
were attached. The displacement of the patient during
treatment was tracked by either internal or external fidu-
cial markers with sub-millimeter accuracy [10].




1 yr.(%) 2 yrs. (%) p
Gender
Male 88 (76.52) 63.67 38.98
Female 27 (23.48) 62.96 57.89 0.523
Age (y.o)
<60 37 (32.17) 56.76 29.63
≧60 78 (74.26) 66.67 45.28 0.207
ECOG
0 49 (42.61) 75.51 54.29
1 53 (46.09) 58.49 36.36
2 13 (11.3) 46.15 20 0.118
Child-Pugh score
A 104 (90.43) 68.27 47.14
B 11 (9.57) 27.27 12.5 <0.001
AJCC stage (7th)
I 21 (18.26) 85.71 78.57
II 18 (15.65) 72.22 60
IIIA 26 (22.61) 69.23 40
IIIB 27 (23.48) 37.03 11.11
IIIC 3 (2.61) 100 0
IV 20 (17.39) 55 37.5 0.001
BCLC
A 12 (10.44) 83.33 75
B 23 (20) 86.26 56.25
C 80 (69.56) 55 31.48 0.080
Tumor type
Solitary 38 (33.04) 81.58 62.5
Multiple 69 (60) 56.52 31.25
Diffuse 8 (6.96) 37.5 33.33 <0.001
Tumor site
Right 91 (79.13) 64.83 42.86
Left 14 (13.04) 53.33 38.46
Bilateral 10 (8.7) 60 0 0.506
Max. tumor diameter (cm)
≦4 40 (34.78) 75 55.17
> 4-9 47 (40.87) 68.82 36.67
≧10 28 (23.48) 48.15 26.32 0.187
Portal vein tumor thrombosis
Yes 34 (29.56) 35.29 12
No 81 (70.43) 75.31 53.7 <0.001
Hepatitis virus
B 59 (51.3) 66.1 36.58
C 42 (36.52) 59.52 46.43
Non B non C 11 (9.57) 81.82 77.78
Table 1 Clinical features and survival of study participants (N = 115)
(Continued)
B + C 3 (2.61) 66.67 0 0.576
AFP Level (ng/ml)
≦20 41 (34.78) 82.93 62.5
> 20-400 31 (27.84) 51.61 17.65
≧400 43 (37.39) 53.49 34.48 0.013
Biochemical changes
Albumin (g/dl) [N = 109]
<3.5 26 (23.85) 46.15 31.81
≥3.5 83 (76.15) 67.47 44.64 0.027
Alkaline Phosphatase (IU/L) [N = 104]
≧129 37 (35.58) 59.45 42.57
<129 67 (64.42) 64.18 36.95 0.893
Platelet (10^3/uL) [N = 109]
<150 52 (47.71) 63.46 35
≧150 57 (52.29) 68.42 48.65 0.291
BED
≦72 Gy10 65 (56.52) 56.92 28.2
73-88 Gy10 8 (6.96) 62.5 28.57
≧89 Gy10 42 (36.52) 76.19 56.25 0.038
Previous treatment
Yes 52 (45.22) 50 37.14
No 63 9(54.78) 55.56 43.18 0.584
Abbreviations: ECOG Eastern Cooperative Oncology Group, AJCC American Joint
Cancer Conference, BCLC Barcelona Clinic Liver Cancer Stage, AFP Alpha-Feto
Protein, BED Biological Effective Dose
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Dose specification and plan evaluation
Prescribed doses, dose per fraction and number of frac-
tions were individualized based on size and location of
tumors, amount of normal liver and organs at risk.
SBRT doses ranging from 26 to 40 Gy in 3-5 fractions
were delivered to tumors > 4 cm and 39 Gy in 3
fractions to tumor ≤ 4 cm. The maximum diameter of
tumors ranged from 1.8-18 cm. The SBRT doses was
converted into normalized total dose at a fraction size
of 2 Gy (NTD2Gy) using the linear quadratic equation
(BED = total dose x (1 + dose per fraction/ α/β), α/β =
10 for early responding tissue, α/β = 3 for late respond-
ing tissue). NTD2 Gy ( α/β = 10) for SBRT ranges from
48.36 Gy to 89.70 Gy. The gross tumor volume (GTV)
included diseases seen on contrast-enhanced CT or
MRI scans. No CTV was further added. The GTV was
directly expanded to 1-3 mm in all directions to cre-
ate the planning target volume (PTV). Modification
of PTV was done if it extended to the dose-limiting
organs, except the normal liver. The prescription iso-
dose line ranged from 59.9-96.9 % of maximum dose
and median isodose line was 79.93 %. The radiation
treatment was delivered with the real-time tracking
system guided by fiducial markers, using the Multi-
Plan Treatment Planning System (version 2.10).
The dose constraints of the protocol for normal liver
(total liver minus cumulative GTV) were specified that a
minimum volume of 700 ml should receive a total dose
less than 15 Gy [17]; 66.7 % of the volume delivered to
the ipsilateral kidney should be less than 15 Gy; the
maximum total dose to any point in the spinal cord
should not exceed 18 Gy, 30 Gy to the stomach, bowel,
duodenum and heart, and 27 Gy to the esophagus [18].
Efforts were made to minimize the dose to the normal
tissues as much as possible.
Follow-up, response, and toxicity assessment
After completion of treatment, the vital sign evaluation,
physical examination, liver function test, and complete
blood test were done to assess acute toxicity. They were
followed every 1 to 2 weeks for the first month and
every 3 months thereafter. Four-phase CT-scans or
dynamic MRI of liver and AFP were obtained 1-2
months and, subsequently, every 3 to 4 months. Tox-
icity grading was according to the Common Toxicity
Criteria Adverse Events, version 4.0. Acute toxicities
were defined as adverse events within 3 months after
SBRT, and late toxicities were those occurring after
3 months. Radiation-induced liver disease was defined
as either classic or nonclassic RILD. Classic RILD was
the presence of nonmalignant ascites and anicteric eleva-
tion of alkaline phosphatase level (twice the upper normal
level) or baseline levels occurred between 2 weeks and
3 months after the completion of irradiation. Nonclassic
RILD, typically occurring between 1 week and 3 months
after therapy, involves elevation of transaminase to at
least 5 times the upper limit of the normal or pretreat-
ment levels within 4 months after completion of irradi-
ation or decline in liver function in the absence of
classic RILD [17, 19], which are the common endpoints
among HCC patients with poor liver function (hepatitis
B infection, Child-Pugh Classic B and C). The diagnosis
of both RILD could be made only in the absence of evi-
dence of tumor progression. Toxicity grading was based
on the worst toxicity recorded.
Tumor response was assessed as described in the
Response Evaluation and Criteria in Solid Tumors
(RECIST) after completion of SBRT. Complete disappear-
ance of the tumor was defined as complete response (CR),
a decrease of more than 30 % in the longest diameter of
target tumors as partial response (PR), a decrease of less
than 30 % or no change as stable (SD), and progression of
more than 20 % as progressive disease (PD). Local recur-
rence-free survival was divided into In-field and out-
field intrahepatic recurrence-free survival, with the In-
field being defined as no new lesion development or no
increase in tumor size within the PTV and the Out-
field as no new liver lesions outside the PTV. Distant
metastasis was defined as recurrence outside the liver;
disease progression was defined as the development of
In-field or out-field intrahepatic recurrence and distant
metastasis.
Statistical analysis
The Overall survival rate (OSR) and Disease-Progression
free survival (DPFS) were estimated from the com-
mencement of SBRT to the last follow-up using the
Kaplan-Meier method. The log-rank test was used to
compare the survival curves over the period of follow-
up time. Univariate hazard ratio (HR) with 95 % confi-
dence intervals were estimated by Cox proportional
hazards regression. Significant factors in univariate Cox
analysis were applied to the multivariate Cox propor-
tional hazards regression analysis based on the Collett's
model selection approach.[20] Analysis of data was
performed using SPSS (SPSS Inc., Chicago, IL, USA)
version 17 software. The statistical significant level was
set at p value <0.05.
Results
Tumor response and local control
The tumor response was evaluated by the change in
maximal diameter of the tumor on CT-scan or MRI 4-6
weeks after treatment completion, followed by every 2
to 3 months subsequently. As summarized in Table 2,
an objective response was observed in 102 of 115
patients (88.7 %). 56 (48.7 %) and 46 (40 %) patients
achieved complete and partial response, respectively;
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stable disease was observed in 10 (8.7 %) patients;
tumor progression was seen in 3 (2.61 %) patients. Pa-
tients achieving complete response had a significantly
favorable survival. 1- and 2-yr OSR of patients with
complete response was 87.5 % and 68.6 %, with median
survival rate of 21 months (13.5-31 months). The OSR
of patients with stable disease was also far better than
those achieving partial response. The 1- and 2-yr OSR
of patients with stable disease was 70 % and 50 %,
respectively, with median survival being 20.5 months
(10-27 months); 1- and 2-yrs OSR of patients with par-
tial response was only 39.1 % and 12.5 %, with median
survival rate of 9 months (5-16 months). Patients with
tumor progression had the worst outcome (none survived
more than 1 year) with median survival of only 4 months
(1-7 months).
Local control was divided into In-field and out-field re-
currence free (IFRF & OFRF) groups. The 1- and 2-year of
IFRF rate were 85.3 % (76.3-91.1) and 81.6 % (71.2–88.6),
while those of OFRF were 51.5 % (41.2-60.8) and 49.5 %
(38.9 -59.2) at 1-and 2-year, respectively.(p = < 0.0001,
Fig. 1). Tumor size (≤4 cm vs. ≥4-9 cm) was the only
significant predictor for the in-field recurrence free (p =
0.041) rate. In contrast, biological effective dose (≤72 Gy
vs. ≥ 89 Gy, p = 0.023) and tumor location (R vs. bilateral
lobe [R/L], p = 0.041) were statistically significant factors
associated with out-field recurrence free rate (Table 3).
Overall survival and prognostic factors
The median follow-up time was 15 months (range, 2-60
months). The overall survival rate (OSR) for 1 and
2 years was 63.5 % (54-71.5 %) and 41.3 % (31.6-50.6 %),
with median survival time of 15 months (4-25 months);
the 1- and 2-year progression-free survival rates were
42.8 % (33.0-52.2 %) and 38.8 % (29.0-48.4 %), with me-
dian progressive-free survival time of 6 months, respect-
ively (Fig. 2). Table 1 shows the clinical features and
survival of the participants.
The analysis of the prognostic factors was based on
survival calculated from the start of SBRT. Multivariate
analysis demonstrated that portal vein tumor thrombosis
(yes vs. no), Child-Pugh score (A vs. B), tumor size
(≤4 cm vs. > 4-9 cm and ≥ 10 cm), and tumor response
after SBRT (CR vs. PR and DP) were the independently
significant predictors of OS (Table 3).
Toxicities
Acute toxicities are listed in Table 4. In general, SBRT is
tolerable. Grade 1-2 Fatigue was the most common seque-
lae and was developed in 59.13 % of the patients. The
other common toxicity was alteration in liver function
test, especially SGOT (56.52 %) and SGPT (49.56 %).
These effects were usually grade 1 or 2 and transient, and
most patients eventually recovered 2-4 weeks later.
Thrombocytopenia was found in 65 patients (61.74 %), 46
patients (40 %) had decreased hemoglobin levels, and 15
(13.04 %) had leukopenia. These toxicities were also tran-
sient and tend to recover to their previous levels 4 weeks
later. Other sequelae include grade 1-2 chest wall pain in
the lower right side found in 20 patients (17.39 %) and
grade 1-2 dermatitis in 3 patients (2.61 %). These were fre-
quently found in patients with HCC closely adhered to ad-
jacent ribs and skin. In order not to compromise the PTV
coverage, rib and skin constraints were not considered.
Fortunately, no severe complication (more than grade 2)
was observed. Aside from ≤ grade 2 nausea and vomiting
(22.61 %), there was no other acute gastrointestinal tox-
icity such as gastroduodenal ulcer and gastroenteritis
colitis.
Eight patients experienced ≥ grade 3 liver function al-
teration within 3 months of SBRT. Five of them were
caused by disease progression and three were nonclassic
RILD. No classic RILD was observed. Among the three
patients with nonclassic RILD, two had underlying HCV
cirrhosis and one had HBV cirrhosis; 2 were BCLC stage
C and 1 was BCLC stage B; all three belonged to Child-
Pugh A. Two of them eventually recovered to their previ-
ous levels 1- 3 months after SBRT. However a 54-year-old
male patient with cT3bN0M0 HCC, HBV liver cirrhosis,
Table 2 Tumor Response, RECIST (N = 115)
Clinical feature N (%) Survival Rate p
1-yr (%) 2-yrs (%)
Complete Response 56 (48.7) 87.5 68.57
Partial Response 46 (40) 39.13 12.5
Stable 10 (8.7) 70 50
Tumor progression 3 (2.61) 0 0 0.001
Fig. 1 In-field recurrence free rate at 1-yr and 2-yrs were 85.3 %
(76.2-91.1) and 81.6 % (71.2-88.6), respectively. Out-field recurrence
free rate at 1-yr and 2-yrs were 51.5 % (41.2-60.8) and 49.5 %
(38.9-59.2), respectively
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Table 3 Prognostic factors: Univariate and Multivariate analysis
Parameter Overall survival In-field recurrence free Out-field recurrence free
UA MA UA MA UA MA
HR (95%CI) P HR (95%CI) P HR(95%CI) P
M vs F 0.531 NS 0.377 NS 0.150 NS
Age (y.o)
<60 vs ≧60 0.217 NS 0.552 NS 0.195 NS
ECOG
0 vs 1 0.052 NS 0.439 NS 0.910 NS
0 vs 2 0.234 NS 0.620 NS
AJCC Stage (7th )
1 vs 2 0.584 NS 0.833 0.974 (0.054-17.559) 0.986 0.380 0.955(0.281-3.251) 0.941
1 vs 3a 0.058 NS 0.240 1.189 (0.108-13.124) 0.888 0.010 1.684(0.540-5.253) 0.369
1 vs 3b 0.001 NS 0.021 5.179 (0.320-83.713) 0.247 0.009 1.549(0.495-4.847) 0.452
1 vs 4 0.063 NS 0.396 0.730 (0.053-10.142) 0.815 0.506 0.841(0.228-3.099) 0.795
BCLC
A vs B 0.502 NS 0.066 NS
B vs C 0.077 NS 0.092 NS
Portal Vein Tumor Thrombosis
N vs Y <0.001 1.774 (1.037-3.036) 0.036 0.035 0.976 (0.167-5694) 0.978 0.054 NS
Child Pugh score
A vs B 0.001 3.183 (1.397-7.255) 0.006 0.221 NS
Hepatitis virus
B vs C 0.766 NS 0.663 NS
B vs Non B/C 0.766 NS 0.57 NS
B vs B + C 0.225 NS
Albumin (g/dl)
≥3.5 vs <3.5 0.033 NS 0.099 NS
Alkaline Phospatase (IU/L)
≥129 vs < 129 0.895 NS 0.999 NS 0.405 NS
Platelet (10^3/uL)
≥150 vs <150 0.302 NS 0.847 NS 0.441 NS
BED
≦72 vs 73-88 0.980 NS 0.808 0.944 (0.316-2.823) 0.918
≦72 vs ≥89 0.016 NS 0.052 NS 0.003 0.423 (0.201-0.890) 0.023
Tumor Size (cm)
≦4 vs >4-9 0.428 2.665 (1.437-4.946) 0.002 0.027 9.210 (1.095-77.473) 0.041 0.872 NS
≦4 vs ≧10 0.085 4.928 (1.794-13.546) 0.002 0.034 6.371 (0.630-64.451) 0.117 0.141 NS
Tumor Type
Solitary vs Multicentric 0.003 NS 0.042 4.173 (0.790-22.044) 0.093 0.003 2.084 (0.880-4.933) 0.095
Solitary vs Diffuse <0.001 NS 0.243 4.994 (0.338-73.688) 0.242 0.674 0.973 (0.186-5.094) 0.974
Location
R vs L 0.903 NS 0.816 NS 0.722 1.231 (0.528-2.872) 0.631
R vs R/L 0.257 NS 0.074 NS 0.006 2.545 (1.038-6.238) 0.041
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Child-Pugh A , went into liver failure and died 2 months
later. Cyberknife SBRT with 40 Gy in 5 fractions was
given for treatment after failure of TACE. HBV DNA
level before treatment was 1,560,000 copies/ml. Anti-
viral drugs were prescribed to the patient but he did
not comply with medication treatment. Reactivation of
HBV DNA level to 1,610,000,000 copies/ml was noted
3 weeks after SBRT, with rapid elevation of transamin-
ase level to 1885 IU/L , other liver function datas sim-
ultaneously deteriorated. However, image studies from
abdomen sonography and MRI of liver shows partial re-
gression of previously treated liver tumor and portal
vein tumor thrombosis, with no evidence of new lesion.
Supportive treatment was given but the patient eventu-
ally died from liver failure 4 weeks later.
Discussion
The results of this study support the fact that Cyberknife
SBRT could be a treatment option for patient ineligible
for local ablation therapies or surgical resection. A large
proportion of our study population had locally advanced
disease or recurrence after standard treatment and
difficult-to-reach tumors. In comparison with other
series, in which SBRT is rarely used on tumor larger
than 7 cm, the median size of the largest tumor in the
current study was 18 cm. Huge tumor (≥10 cm) com-
prise 23.48 % of the cases, while portal vein tumor
thrombosis was present in 29.56 % of patients. In a large
prospective study of 102 patients with locally advanced
HCC treated with a six-fraction SBRT regimen, max-
imum tumor size was less than 7.2 cm. Bujold et al. re-
ported a 1-year local control rate of 87 % [3]. Mendez-
Romero et al first described the results of prescribing 25
to 37.5 Gy in three to five fractions to 25 patients with
inoperable HCC and liver metastases in another pro-
spective study. Median lesion size was 3.2 cm. (range
0.5-7.2 cm). Local control rate at 1 and 2 years were
94 % and 82 % [21]. In our study, despite the large num-
ber of patients with large tumor burden (40.87 % patient
was >4-9 cm, 23.48 % patient was ≥ 10 cm) , the 1-year
and 2-year in-field recurrence free rate of 85.3 % and
81 %, were encouraging. Tumor size was the most sig-
nificant factor affecting local control. Most HCC is a
multicentric disease and the patients tended to have a
higher risk of local recurrence after treatment [22]. Des-
pite high in-field recurrence free after SBRT in our
study, similar to other treatment modalities, intrahepatic
out-field recurrence remains the major problem. Thus,
combination of SBRT and systemic therapies is reason-
able. A recent retrospective analysis of 23 patients with
advanced HCC treated with concurrent hypofractionated
radiation therapy (52.5 Gy in 15 fractions) with sunitinib
(Sutent;Pfizer, New York, NY) demonstrated prolonga-
tion of time to progression from 4 months to 10 months
[23]. However, an early phase 1 study combining SBRT
with concurrent sorafenib by the University of Toronto
suggested that higher dose of sorafenib (400 mg daily),
when combined with radiation, could delivered higher
values of effective liver volumes (Veff 30 %-60 %) irradi-
ated, yielding a significant (grade 3+) toxicity [24]. An
ongoing RTOG 1112 phase 3 study of sorafenib versus
SBRT followed by sorafenib in HCC is being conducted.
In this study, sorafenib will be delivered after completion
Table 3 Prognostic factors: Univariate and Multivariate analysis (Continued)
AFP (ng/ml)
≦20 vs 20-400 0.005 NS 0.070 NS 0.360 NS
≤20vs ≥400 0.066 NS 0.117 NS 0.985 NS
Previous treatment
No vs Yes 0.592 NS 0.318 NS 0.821 NS
Abbreviations as in Table 1
a. Identify the predictors significant at p-value < 0.2. b. The effects met the 0.1 level for forward and backward method entry into the multivariate survival model
based on Collett’s model selection approach. c. p-value of <0.05 was significant
Fig. 2 Overall survival curve of 115 patients treated with Cyberknife
SBRT. 1-yr and 2-yrs OSR were 63.5 % (54-71.5 %) and 41.3 % (31.6-
50.6 %), median survival times was 15 months (4-25 mos.), While 1-yr
and 2-yrs Progression-free survival rate were 42.8 % (33.0-52.2 %)
and 38.8 % (29.0-48.4 %), median progressive-free survival times was
6 months, respectively
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of radiation, rather than concurrently with radiation, to
reduce the risk of treatment toxicity.
In our study, 1- and 2-yr OSR was 63.5 % (54-71.5 %)
and 41.3 % (31.6-50.6 %), respectively. Median survival
was 15 months and median progressive-free survival
was 6 months. Objective response (CR + PR) of 88.7 %
compared favorably with best supportive care, even bet-
ter than sorafenib and sunitinib, which are the only
other options for this patient population. In a random-
ized phase 3 trial of sunitinib vs. sorafenib for advanced
HCC by Cheng et al., the median survival for sunitinib
was 7.9 months while sorafenib was 10.2 months; the
median progression-free survival was 3.6 vs. 3.0 months
[25]. One other study by Llovet et al. reported a 1-yr
OSR of 44 % and median survival of 10.7 months for
sorafenib patients [6]. A large randomized trial of
Sorafenib from Asia-Pacific region showed a median
overall survival of only 6-5 months and median to pro-
gression of 2.8 months [7].
Consistent with other studies, portal vein tumor
thrombosis remains the established prognostic factors
in the study series. The median survival was 8 months
vs. 17.5 months for HCC with and without PVTT; 1-
and 2-year overall survival was 35.3 % and 12.50 % vs.
75.31 % and 53.7 %. A retrospective study by Xi et al.
reported a median survival of 13 months and a 1-year
overall survival of 50.3 % for 41 HCC patients with
PVTT and/or with inferior vena cava thrombus treated
to a median dose of 36 Gy in 6 fractions targeting the
tumor thrombus [26]. Another prospective study from
University of Toronto reported a median survival of
10.6 months versus 21.5 months for HCC with and
without PVTT, respectively, with a total radiation dose
ranging from 24-54 Gy in 6 fractionations schema [3].
Compared with other studies series using SBRT for HCC
with PVTT, a larger proportion of our patients with
PVTT (29.56 %) had a large tumor burden (>4-9 cm in
40.87 % of patients, ≥ 10 cm in 23.48 % of patients) and
66.9 % of tumor types were multicentric and diffuse in our
present cohort, which partly explain why OS was lower
than expected in our study. Child-Pugh score, tumor size
and tumor response are other major independent risk
factors for overall survival. Tumor size is the only inde-
pendent predictive factor for In-field recurrence free rate.
Patients with tumors ≤ 4 cm had significantly better
outcomes than those with > 4 cm and ≥ 10 cm tumors.
Tumors located mainly in the right lobe and a higher bio-
logically effective dose were the major predictive factors
for out-field recurrence free rate. In our study series, BED
89 Gy (39 Gy in 3 fractions) was given to small (≤4 cm.),
solitary and peripheral tumors, expectedly to have a better
local control and less chance of developing a multicentric
type of HCC. In an earlier study from RTOG report, a
high-dose group showed better results [27]. Park et al,
show a dose-response relationship in the local control rate
of primary HCC [28]. Another study by Park et al,
reported that BED10 > 50 Gy had a significant better
response rate (complete or partial response) of 72.8 %
compared with 46.7 % with BED10 ≤ 50Gy (p = 0.0299)
[29]. While possible hypothesis for higher chance of out-
field recurrence free rate from higher BED10, is the
enhanced antitumor immunity after SBRT of tumor at 1
site contributes to rejection of metastatic lesion at distant
sites, so called abscopal effect reported by Postow et al
Table 4 Toxicity, CTCAE v 40
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total
No. % No. % No. % No. % No. % %
Fatigue 64 55.65 2 1.74 1 0.87 0 0 0 0 59.13
Pain (RUQ/ chestwall) 18 15.62 2 1.74 0 0 0 0 0 0 17.39
Biochemical
SGOT 49 42.61 8 6.96 7 6.09 0 0 1 0.87 56.52
SGPT 42 36.52 8 6.96 6 5.22 0 0 1 0.87 49.56
Alk.P 36 31.3 3 2.61 4 3.48 0 0 0 0 37.3
Bilirubin 12 10.43 3 2.61 1 0.87 0 0 1 0.87 14.78
Albumin 38 33.04 6 5.22 0 0 0 0 0 0 38.26
Hematologic
Anemia 44 38.26 2 1.74 0 0 0 0 0 0 40
leukopenia 9 7.83 6 5.22 0 0 0 0 0 0 13.04
Thrombo-cytopenia 45 39.13 20 17.39 6 5.22 0 0 0 0 61.74
Nausea/
vomiting
24 20.87 2 1.74 0 0 0 0 0 0 22.61
Dermatitis 1 0.87 2 1.74 0 0 0 0 0 0 2.61
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[30]. However, the clinical evidence was found only in
two Melanoma patients. Another preclinical study on
mice by Lee et al [31] has reported a similar enhance-
ment of antitumor immunity after high dose irradiation
of local tumor. These results are clearly exciting but
much more information is needed to recommend the
most optimal radiation therapy treatments.
The use of Cyberknife SBRT to treat primary HCC is an
important aspect of our study. In comparison with con-
ventional fractionated RT, Cyberknife SBRT demonstrates
its benefits for achieving highly conformal dose distri-
butions with respiratory synchronization while sparing
the adjacent normal liver [32]. This allows higher bio-
logically effective dose to be delivered without in-
creased incidence of liver toxicities, and better local
control may be achieved. In terms of toxicity, the
present study shows that Cyberknife SBRT is feasible
and safe in primary HCC patients, which is consistent
with the findings of previous SBRT study [6, 21]. Of the
3 documented cases of RILD in our study, 2 eventually
recovered and one died as a result of radiation-induced
liver failure 2 months after treatment. And the cause of
RILD was the reactivation of hepatitis B virus. Kim et al
demonstrated that 3D-CRT can induce HBV reactiva-
tion in patients with HBV-related HCC. They defined
elevated transaminase level, 2.5 fold the upper limit of
normal accompanying an increase of > 2 log10 copies
/mL in HBV DNA as a criteria for HBV exacerbation in
patient undergoing 3D-CRT for HBV-related HCC [13]
. Cheng et al, found that HCC patients with underlying
hepatitis B virus carriers or Child-Pugh B cirrhosis
showed signifcantly greater susceptibility to radiation-
induced liver disease after three-dimensional conformal
radiotherapy. Asian patients with HCC usually have
viral hepatitis, therefore, dose distribution in liver is
crucial to the preservation of liver function [15]. Huang
et al. and Janoray et al. reported the RILD incidence rate
of 5.5 % and 0 or 9 %, respectively, using Cyberknife SBRT
[33, 34]. Earlier reports by Takeda et al. and Tse et al. also
reported no serious SBRT-related toxicities [8, 35]. In
contrast, there were much more treatment-related com-
plications with other local therapies. In cases of TACE,
rate of acute liver failure is approximately 7.5 % and treat-
ment related mortality rate is 2.4 % after TACE [36]. For
RFA, major complications developed in 2.2 %-12.6 % of
patients, and the mortality rate is 0-0.8 % [37]. RILD
incidence was low and most cases were reversible after
Cyberknife SBRT for HCC. However, further prospect-
ive studies might be required to determine the predictive
factors of radiation-induced liver disease and optimal dos-
ing regimen.
The major limitation of our study is that it was a
retrospective single-institution study with small and
hetergenous sample size. However, this is the largest
study to date that focused on the use of Cyberknife
SBRT for inoperable HCC.
Conclusions
In the present study, excellent in-field control was ob-
tained for Cyberknfie SBRT in HCC. In-field recurrence
free rate at 2-years was 81.6 %, tumor response rate
(CR + PR) was 88 %, and 1- and 2-year overall survival
rates were 63.5 % and 41.3 %, which was encouraging.
The acute toxicity was relatively mild and tolerable. In
a population of patients for whom curative local treatment
is not applicable, SBRT can lead to sustained local control
and a higher survival rate than historical controls, with a
low risk of morbidity. Out-field recurrence is still the
major cause of failure, providing a rationale for combining
SBRT and regional or systemic therapies. Further study is
required to define the optimal radiation dose and fraction-
ation for future SBRT treatment.
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